End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
10.19
CNY
|
-2.02%
|
|
-4.14%
|
-27.06%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,405
|
2,221
|
1,647
|
1,839
|
2,138
|
2,459
|
Enterprise Value (EV)
1 |
2,198
|
2,203
|
1,709
|
1,899
|
2,210
|
2,507
|
P/E ratio
|
39.5
x
|
81.7
x
|
-24.5
x
|
-78.8
x
|
-57.3
x
|
258
x
|
Yield
|
1.43%
|
0.22%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.51
x
|
7.57
x
|
13.7
x
|
7.44
x
|
8.09
x
|
7.92
x
|
EV / Revenue
|
5.04
x
|
7.51
x
|
14.2
x
|
7.69
x
|
8.36
x
|
8.07
x
|
EV / EBITDA
|
30.8
x
|
58.8
x
|
-36
x
|
360
x
|
-229
x
|
56.3
x
|
EV / FCF
|
-15.1
x
|
-15.7
x
|
-40.2
x
|
67.4
x
|
1,053
x
|
-94.1
x
|
FCF Yield
|
-6.61%
|
-6.37%
|
-2.49%
|
1.48%
|
0.09%
|
-1.06%
|
Price to Book
|
3.62
x
|
3.37
x
|
2.81
x
|
3.26
x
|
4.06
x
|
4.59
x
|
Nbr of stocks (in thousands)
|
176,000
|
176,000
|
176,000
|
176,000
|
176,000
|
176,000
|
Reference price
2 |
13.66
|
12.62
|
9.360
|
10.45
|
12.15
|
13.97
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/29/21
|
4/26/22
|
4/19/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
436.3
|
293.5
|
120.7
|
247.1
|
264.2
|
310.6
|
EBITDA
1 |
71.39
|
37.46
|
-47.46
|
5.275
|
-9.667
|
44.54
|
EBIT
1 |
57.23
|
17.49
|
-76.65
|
-25.99
|
-42.44
|
11.65
|
Operating Margin
|
13.12%
|
5.96%
|
-63.51%
|
-10.52%
|
-16.07%
|
3.75%
|
Earnings before Tax (EBT)
1 |
70
|
32.23
|
-48.83
|
-13.77
|
-29.67
|
22.36
|
Net income
1 |
60.9
|
27.48
|
-67.22
|
-23.34
|
-37.31
|
9.534
|
Net margin
|
13.96%
|
9.37%
|
-55.7%
|
-9.45%
|
-14.12%
|
3.07%
|
EPS
2 |
0.3461
|
0.1545
|
-0.3819
|
-0.1326
|
-0.2120
|
0.0542
|
Free Cash Flow
1 |
-145.2
|
-140.3
|
-42.52
|
28.18
|
2.098
|
-26.63
|
FCF margin
|
-33.28%
|
-47.81%
|
-35.23%
|
11.41%
|
0.79%
|
-8.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
534.28%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1955
|
0.0273
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/29/21
|
4/26/22
|
4/19/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
62
|
59.7
|
71.2
|
47.9
|
Net Cash position
1 |
207
|
18
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-1.306
x
|
11.32
x
|
-7.361
x
|
1.075
x
|
Free Cash Flow
1 |
-145
|
-140
|
-42.5
|
28.2
|
2.1
|
-26.6
|
ROE (net income / shareholders' equity)
|
9.5%
|
4.16%
|
-10.8%
|
-4.06%
|
-6.85%
|
1.8%
|
ROA (Net income/ Total Assets)
|
4.86%
|
1.37%
|
-5.81%
|
-1.91%
|
-3.07%
|
0.88%
|
Assets
1 |
1,252
|
2,001
|
1,158
|
1,219
|
1,217
|
1,088
|
Book Value Per Share
2 |
3.770
|
3.740
|
3.340
|
3.200
|
2.990
|
3.040
|
Cash Flow per Share
2 |
1.170
|
0.5500
|
0.3300
|
0.6400
|
0.4100
|
0.4900
|
Capex
1 |
135
|
112
|
64.1
|
31.5
|
23.9
|
30.6
|
Capex / Sales
|
30.91%
|
38.07%
|
53.08%
|
12.74%
|
9.06%
|
9.84%
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/29/21
|
4/26/22
|
4/19/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -27.06% | 248M | | +21.28% | 43.92B | | +24.47% | 23.09B | | +19.22% | 15.35B | | +12.87% | 13.61B | | +44.67% | 12.02B | | -9.92% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.07% | 5.6B |
Generic Pharmaceuticals
|